PRODUCT NEWS

NEWSROOM

These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.


Claritin
Mar. 19, 2010   Non-Drowsy Claritin® Partners With Kara Dioguardi, Judge on TV's Hottest Show, To Collect Inspirational Stories From Allergy Sufferers Across America
     
Coppertone
Jul. 07, 2010   Coppertone® Solar Research Center Releases “Suncare 2020” Symposium Key Insights
Mar. 05, 2010   Coppertone® Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology
     
DR. SCHOLL'S® Custom Fit™
Jul. 13, 2010   DR. SCHOLL'S® Custom Fit™ Orthotic Inserts Now Available in Stores Nationwide
     
DR. SCHOLL'S® FOR HER
Apr. 08, 2010   DR. SCHOLL'S® FOR HER Joins Forces with Style Expert Stacy London to Help Women Achieve Style and Comfort
     
COZAAR® (losartan potassium)
Patient Product Information
Nov. 17, 2009   Higher Dose of Merck's COZAAR® (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study
     
DULERA® (mometasone furoate and formoterol fumarate dihydrate)
Medication Guide
Jun. 24, 2010   FDA Approves Merck's DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older
     
FOSAMAX® (ALENDRONATE SODIUM TABLETS)
Jun. 25, 2010   Merck Challenges Verdict in Federal FOSAMAX® (alendronate sodium) Trial
Jun. 07, 2010   Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court
May 05, 2010   Merck Wins Second Federal FOSAMAX® (alendronate sodium) Bellwether Trial
Apr. 19, 2010   Merck Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court
Mar. 9, 2010   Statement by Merck & Co., Inc., Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw
Nov. 23, 2009   Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX® (alendronate sodium)
     
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
Patient Product Information
Feb. 17, 2010   In Phase III Data Merck's GARDASIL® Was Efficacious Against Anal Disease Caused by HPV 6,11,16, and 18
Oct. 21, 2009   CDC Advisory Committee on Immunization Practices Votes for Permissive Use and for Vaccines for Children Funding for GARDASIL® for Boys and Young Men
Oct. 16, 2009   FDA Approves GARDASIL® for Use in Boys and Young Men
Sep. 09, 2009   FDA Advisory Committee Recommends Approval for Use of GARDASIL® in Boys and Men
Aug. 20, 2009   Merck is Pleased the FDA and CDC Re-affirm the Safety Profile of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant]
Aug. 18, 2009   New Study Reinforces Safety Profile of GARDASIL®, the Cervical Cancer Vaccine
May 26, 2009   GARDASIL® is First Cervical Cancer Vaccine to Receive WHO Pre-qualification
Jan. 09, 2009   Merck & Co., Inc., Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL® in Women Ages 27 through 45
     
ISENTRESS™ (raltegravir)
Patient Product Information
May 06, 2010   Merck and The ADAP Crisis Task Force Announce Key Initiatives to Help Provide Funding Relief to AIDS Drug Assistance Programs (ADAPs) across the U.S.
Feb. 17, 2010   New Data on ISENTRESS® (raltegravir) Presented at the Conference on Retroviruses and Opportunistic Infections (CROI)
Dec. 1, 2009   U.S. Department of Health & Human Services Recommends Merck’s First-in-Class Integrase Inhibitor ISENTRESS® (raltegravir) Tablets, in Combination Therapy, as one of four Preferred Regimens for Treatment-Naïve Patients with HIV-1 Infection
Sep. 13, 2009   Merck's ISENTRESS® (raltegravir) Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients
Jul. 31, 2009   FDA Approves Expanded Use of ISENTRESS® (raltegravir) in Combination Therapy for Adult Patients with HIV-1 Infection to Include Patients Not Previously Treated with HIV Medicines
Jul. 20, 2009   ISENTRESS® (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy
     
JANUMET™(sitagliptin/metformin HCl) tablets
Medication Guide
Jun. 26, 2010   In a New Study, Treatment With JANUMET® (sitagliptin/metformin), Merck’s Diabetes Medicine, Resulted In Significantly Greater Blood Sugar Lowering Compared with Pioglitazone
Sep. 25, 2009   Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin
Jun. 08, 2009   Initial Therapy with JANUMET™ (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes
Jun. 06, 2009   In Investigational Studies, New Uses of JANUVIATM(sitagliptin) in Combination with Other Diabetes Medicines Resulted In Significant Blood Sugar-Lowering Efficacy for Patients with Type 2 Diabetes
     
JANUVIA™ (sitagliptin)
Medication Guide
Jun. 28, 2010   In a Post-Hoc Analysis, JANUVIA® (sitagliptin), Merck’s Diabetes Medicine, Compared with a Sulfonylurea (Glipizide) on Composite Endpoint of Lower Blood Sugar, No Hypoglycemia and No Weight Gain
Sep. 25, 2009   Merck Receives Positive CHMP Opinion for JANUVIA® (sitagliptin) and JANUMET® (sitagliptin/metformin) as Add-On to Insulin in the European Union
Jun. 08, 2009   Initial Therapy with Janumet™ (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes
Jun. 06, 2009   Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin
Nov. 21 2008   New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
     
SAFLUTAN® (tafluprost)
Sep. 03, 2009   Merck Launches SAFLUTAN® (tafluprost) in International Markets
     
SAPHRIS® (tafluprost)
Jun. 25, 2010   Committee for Medicinal Products for Human Use (CHMP) Issues Opinion on European Regulatory Filing for Merck's Atypical Antipsychotic Medication SYCREST® (asenapine)
     
SINGULAIR® (montelukast)
Patient Product Information
Aug. 19, 2009   Merck Wins SINGULAIR® Patent Infringement Lawsuit
Jun. 12, 2009   Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium)
May 29, 2009   Merck Statement on United States Patent & Trademark Office Decision to Reexamine the SINGULAIR® Patent
Jan. 13, 2009   Merck Statement in Response to the FDA's Update Regarding a Safety Review of SINGULAIR® (montelukast)
     
STAXYN™ (vardenafil HCl)
  Full Prescribing Information
Jun. 18, 2010   FDA Approves STAXYN™ (vardenafil HCl) Orally Disintegrating Tablets For Erectile Dysfunction (ED)
     
TEMODAR® (temozolomide) Capsules and TEMODAR® (temozolomide) for Injection
 
Jan 26, 2010   U.S. District Court Rules Against Merck in TEMODAR® (temozolomide) Patent Lawsuit
     
VYTORIN® (ezetimibe/simvastatin)
Patient Product Information
Dec. 22, 2009   FDA Follow-up Communication Regarding SEAS Trial
Nov. 15, 2009   Merck Expresses Confidence in the Efficacy and Safety Profiles of ZETIA® (ezetimibe) and VYTORIN® (ezetimibe/simvastatin) as Effective Medicines for Managing Elevated Cholesterol
     
ZEGERID OTC™
Apr. 1, 2010   ZEGERID OTC™ Hits Store Shelves; Offers Only Patented Dual-Ingredient Option for 24 Hour Frequent Heartburn Relief without a Prescription
Dec. 1, 2009   FDA Approves ZEGERID OTC™ for Over-the-Counter Treatment of Frequent Heartburn
     
ZETIA
Patient Product Information
May 10, 2010   Merck Settles Patent Infringement Case for Zetia® (ezetimibe)
     
ZOSTAVAX
Patient Product Information
May 13, 2010   New Large Study Results Confirm Safety Profile of ZOSTAVAX®, Merck's Shingles Vaccine, in People Aged 60 or Older
     

 

TRUSTe - Click to Verify   This Web This Web Accessibility icon serves as a link to download eSSENTIAL Accessibility assistive technology software for individuals with physical disabilities. It is being featured as part of a Disability Community Involvement initiative that reflects our commitment to Diversity, Inclusion,Corporate Citizenship and Social Responsibility.